why choose us

300×250 Ad Slot

Drug FDA Status

Showing 10 of 149 result(s) (Page 1 of 15)
Drug Name: Myqorzo

Active Ingredient: aficamten

Approval Date: 2025-12-19

Description: To treat symptomatic obstructive hypertrophic cardiomyopathy

Drug Name: Exdensur

Active Ingredient: depemokimab-ulaa

Approval Date: 2025-12-16

Description: To treat severe asthma characterized by an eosinophilic phenotype as an add-on maintenance therapy

Drug Name: Lerochol

Active Ingredient: lerodalcibep-liga

Approval Date: 2025-12-12

Description: To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

Drug Name: Nuzolvence

Active Ingredient: zoliflodacin

Approval Date: 2025-12-12

Description: To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae

Drug Name: Cardamyst

Active Ingredient: etripamil

Approval Date: 2025-12-12

Description: To treat episodes of paroxysmal supraventricular tachycardia

Drug Name: Voyxact

Active Ingredient: sibeprenlimab-szsi

Approval Date: 2025-11-25

Description: To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

Drug Name: Hyrnuo

Active Ingredient: sevabertinib

Approval Date: 2025-11-19

Description: To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

Drug Name: Redemplo

Active Ingredient: plozasiran

Approval Date: 2025-11-18

Description: To reduce triglycerides in adults with familial chylomicronemia syndrome

Drug Name: Komzifti

Active Ingredient: ziftomenib

Approval Date: 2025-11-13

Description: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

Drug Name: Kygevvi

Active Ingredient: doxecitine and doxribtimine

Approval Date: 2025-11-03

Description: To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

300×250 Ad Slot